| Entry |
|
|---|
| Name |
Tozinameran (JAN);
COVID-19 mRNA vaccine (nucleoside-modified);
Comirnaty (TN);
Pfizer-biontech Covid-19 vaccine (TN) |
|---|
| Product |
|
|---|
| Other |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 6313 |
|
|---|
| Efficacy |
Active immunization (SARS-CoV-2) |
|---|
| Disease |
Prevention of COVID-19 [DS: H02398] |
|---|
| Comment |
Tozinameran is mRNA encoding full length of spike protein analog of SARS-CoV-2
|
|---|
| Target |
SARS-CoV-2 spike glycoprotein [KO: K24152] |
|---|
| Pathway |
| ko05171 | Coronavirus disease - COVID-19 |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
63 Biological preparations
631 Vaccines
6313 Viral vaccines
D11971 Tozinameran (JAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11971
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11971
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11971
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11971
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
